Haw Par Corporation Limited (HAWPF)
OTCMKTS · Delayed Price · Currency is USD
12.45
+0.21 (1.76%)
At close: Jan 16, 2026
Haw Par Corporation Revenue
Haw Par Corporation had revenue of 126.34M SGD in the half year ending June 30, 2025, with 13.70% growth. This brings the company's revenue in the last twelve months to 253.05M, up 5.85% year-over-year. In the year 2024, Haw Par Corporation had annual revenue of 244.82M with 5.50% growth.
Revenue (ttm)
253.05M SGD
Revenue Growth
+5.85%
P/S Ratio
15.08
Revenue / Employee
425.29K SGD
Employees
595
Market Cap
3.00B USD
Revenue Chart
* This company reports financials in SGD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 244.82M | 12.76M | 5.50% |
| Dec 31, 2023 | 232.06M | 49.97M | 27.44% |
| Dec 31, 2022 | 182.09M | 40.91M | 28.98% |
| Dec 31, 2021 | 141.18M | 30.15M | 27.15% |
| Dec 31, 2020 | 111.03M | -132.96M | -54.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
| Tian'an Technology Group | 2.12M |